Tesamorelin
Also known as: Egrifta
Overview
Tesamorelin is a synthetic analogue of GHRH approved by the FDA for HIV-associated lipodystrophy. It has demonstrated significant reductions in visceral adipose tissue and improvements in cognitive function. It is one of the few peptides with FDA approval, lending it a higher level of clinical validation.
How it works
Binds to GHRH receptors on pituitary somatotrophs, stimulating GH synthesis and release. The resulting increase in IGF-1 promotes lipolysis particularly in visceral adipose tissue. Also demonstrates direct effects on lipid metabolism and may have neuroprotective properties.
Primary uses
- Visceral fat reduction
- Growth hormone stimulation
- IGF-1 increase
- Cognitive function
- Lipid profile improvement
What to expect
Based on reported user experiences and available research, here is a general timeline of effects:
Days 1–14
- GHRH receptor activation begins immediately
- Some users report improved energy and sleep within the first two weeks
Days 14–84
- Visceral fat reduction is typically measurable by week 8 in clinical studies
- IGF-1 is rising — muscle preservation and recovery improving
- Cognitive function improvements are beginning to emerge
Days 84–999
- Significant visceral fat reduction is well established at 3+ months
- Neuroprotective and cognitive benefits are accumulating
- Lipid profile improvements are measurable with sustained use
Storage and preparation
Store lyophilised at 2-8°C refrigerated. Do not freeze. Once reconstituted, use within 3 hours or discard.
Reconstitute with sterile water for injection provided with kit. Inject water slowly into vial and gently roll — do not shake. Use immediately after reconstitution.
Research
The following studies are available via PubMed:
Track your compound stack in Lymity
Log doses, track cycles, and see your timeline benefits in the app